David Oh, MD, PhD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address513 Parnassus Avenue, HSE, #301
San Francisco CA 94143
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Harvard CollegeAB2000Biochemical Sciences
    Stanford University School of MedicineMD/PhD2011Medicine, Physiology
    University of California, San FranciscoResidency2014Internal Medicine
    University of California, San FranciscoFellowship2017Hematology/Oncology
    Collapse Awards and Honors
    University of California, San Francisco2015Clinical Fellow Award
    Conquer Cancer Foundation of American Society of Clinical Oncology 2016Merit Award
    University of California, San Francisco2016Molecular Pathology of Cancer T32
    Conquer Cancer Foundation of American Society of Clinical Oncology2017Young Investigator Award
    Bladder Cancer Advocacy Network2018Young Investigator Award
    Prostate Cancer Foundation2018Young Investigator Award
    Damon Runyon Cancer Research Foundation2021Clinical Investigator Award

    Collapse Overview 
    Collapse Overview
    I am a physician-scientist focused on developing novel immunotherapies with enhanced activity and reduced toxicity, for patients with solid cancers.

    Clinically, I see patients in the Cancer Immunotherapy Program where I lead numerous early phase trials, with a particular focus on adoptive cell therapies for solid tumors (CAR-T and TCR). I have also led trials of intratumoral immunotherapy and next-generation cytokine therapy.

    In the laboratory, I run an extramurally funded translational program focused on the role of cytotoxic immune effectors in anti-tumor responses as well as immune-related adverse events (IRAEs) after immunotherapy. This work spans high-resolution multiomic interrogation and functional validation using patient samples, as well as murine model systems.

    Collapse Research 
    Collapse Research Activities and Funding
    Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events
    NIH K08AI139375Mar 1, 2019 - Feb 29, 2024
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Collaboration Interests

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis. Nat Commun. 2024 Feb 19; 15(1):1493. Mennillo E, Kim YJ, Lee G, Rusu I, Patel RK, Dorman LC, Flynn E, Li S, Bain JL, Andersen C, Rao A, Tamaki S, Tsui J, Shen A, Lotstein ML, Rahim M, Naser M, Bernard-Vazquez F, Eckalbar W, Cho SJ, Beck K, El-Nachef N, Lewin S, Selvig DR, Terdiman JP, Mahadevan U, Oh DY, Fragiadakis GK, Pisco A, Combes AJ, Kattah MG. PMID: 38374043; PMCID: PMC10876948.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Efficacy outcomes and biomarker analysis from phase II trial of escalating doses of neoadjuvant atezolizumab in patients with muscle-invasive urothelial carcinoma ineligible for cisplatin-based chemotherapy. Journal of Clinical Oncology. 2024 Feb 1; 42(4_suppl):602-602. Koshkin KV, Jindal JT, He HJ, Zhang ZL, Galang GC, Natesan ND, Kumar KV, Zhu ZX, Chou CJ, Aggarwal AR, Small SE, Meng MM, Porten PS, Oh OD, Fong FL, Friedlander FT. .
      View in: Publisher Site   Mentions:
    3. Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis. bioRxiv. 2024 Jan 03. Mennillo E, Kim YJ, Lee G, Rusu I, Patel RK, Dorman LC, Flynn E, Li S, Bain JL, Andersen C, Rao A, Tamaki S, Tsui J, Shen A, Lotstein ML, Rahim M, Naser M, Bernard-Vazquez F, Eckalbar W, Cho SJ, Beck K, El-Nachef N, Lewin S, Selvig DR, Terdiman JP, Mahadevan U, Oh DY, Fragiadakis GK, Pisco A, Combes AJ, Kattah MG. PMID: 36711576; PMCID: PMC9882264.
      View in: PubMed   Mentions:
    4. Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer. Clin Genitourin Cancer. 2023 Dec 17. Emperumal CP, Villa A, Hwang C, Oh D, Fong L, Aggarwal R, Keenan BP. PMID: 38185609.
      View in: PubMed   Mentions:    Fields:    
    5. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023 Nov; 24(11):1266-1276. Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, Hope TA. PMID: 37922930; PMCID: PMC10667020.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    6. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. Nat Med. 2023 08; 29(8):2099-2109. Hassan R, Butler M, O'Cearbhaill RE, Oh DY, Johnson M, Zikaras K, Smalley M, Ross M, Tanyi JL, Ghafoor A, Shah NN, Saboury B, Cao L, Quintás-Cardama A, Hong D. PMID: 37501016; PMCID: PMC10427427.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    7. Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors. Journal of Clinical Oncology. 2023 Jun 1; 41(16_suppl):8537-8537. Hassan HR, Butler BM, Oh OD, O'Cearbhaill OR, MacMullen ML, Jeter JE, Guha GU, Muzithras MV, Zikaras ZK, Johnson JM, Tanyi TJ, Ghafoor GA, Tighe TR, Smalley SM, Quintas-Cardama QA, Hong HD. .
      View in: Publisher Site   Mentions:
    8. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2023 03; 615(7953):687-696. Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, Yuen B, Dalmas O, Heeringa K, Sennino B, Conroy A, Bethune MT, Mende I, White W, Kukreja M, Gunturu S, Humphrey E, Hussaini A, An D, Litterman AJ, Quach BB, Ng AHC, Lu Y, Smith C, Campbell KM, Anaya D, Skrdlant L, Huang EY, Mendoza V, Mathur J, Dengler L, Purandare B, Moot R, Yi MC, Funke R, Sibley A, Stallings-Schmitt T, Oh DY, Chmielowski B, Abedi M, Yuan Y, Sosman JA, Lee SM, Schoenfeld AJ, Baltimore D, Heath JR, Franzusoff A, Ribas A, Rao AV, Mandl SJ. PMID: 36356599; PMCID: PMC9768791.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCellsCTClinical Trials
    9. Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer. Sci Immunol. 2022 07; 7(73):eabq2630. Kwon H, Schafer JM, Song NJ, Kaneko S, Li A, Xiao T, Ma A, Allen C, Das K, Zhou L, Riesenberg B, Chang Y, Weltge P, Velegraki M, Oh DY, Fong L, Ma Q, Sundi D, Chung D, Li X, Li Z. PMID: 35420889; PMCID: PMC9374385.
      View in: PubMed   Mentions: 42     Fields:    Translation:AnimalsCells
    10. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2022 Feb 20; 40(6_suppl):98-98. Slovin SS, Dorff DT, Falchook FG, Wei WX, Gao GX, McKay MR, Oh OD, Wibmer WA, Spear SM, McCaigue MJ, Shedlock SD, Dhar DM, Coronella CJ, Martin MC, Ghodussi GM, Murphy MA, Ostertag OE. .
      View in: Publisher Site   Mentions:
    11. Preparation of Radiolabeled Antibodies for Nuclear Medicine Applications in Immuno-Oncology. Methods Mol Biol. 2022; 2393:829-839. Wei J, Oh DY, Evans MJ. PMID: 34837214.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    12. Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox. Immunity. 2021 12 14; 54(12):2701-2711. Oh DY, Fong L. PMID: 34910940; PMCID: PMC8809482.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansAnimalsCells
    13. Toward a better understanding of T cells in cancer. Cancer Cell. 2021 12 13; 39(12):1549-1552. Oh DY, Fong L, Newell EW, Turk MJ, Chi H, Chang HY, Satpathy AT, Fairfax B, Silva-Santos B, Lantz O. PMID: 34906313.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    14. In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET. ACS Cent Sci. 2021 Oct 27; 7(10):1638-1649. Zhao N, Bardine C, Lourenço AL, Wang YH, Huang Y, Cleary SJ, Wilson DM, Oh DY, Fong L, Looney MR, Evans MJ, Craik CS. PMID: 34729407; PMCID: PMC8554823.
      View in: PubMed   Mentions: 18  
    15. Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy. Anticancer Res. 2021 Jun; 41(6):2985-2992. Keenan BP, VAN Loon K, Khilnani AD, Fidelman N, Behr SC, Atreya CE, Oh DY. PMID: 34083289; PMCID: PMC8631311.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    16. An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):2573-2573. Tsimberidou TA, Drakaki DA, Khalil KD, Kummar KS, Hodi HF, Oh OD, Cabanski CC, Tezlaff TM, LaVallee LT, Spasic SM, Nissola NL, Kitch KL, Bayless BN, Selinsky SC, Ayran AJ, O'Donnell-Tormey OJ, Hubbard-Lucey HV, Dugan DU, Allison AJ, Sharma SP. .
      View in: Publisher Site   Mentions:
    17. Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423). Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):e16510-e16510. Natesan ND, Zhang ZL, Oh OD, Porten PS, Meng MM, Pruthi PR, Cooperberg CM, Carroll CP, Chou CJ, Borno BH, Bose BR, Desai DA, Kwon KD, Wong WA, Feng FF, Aggarwal AR, Small SE, Fong FL, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    18. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. J Immunother Cancer. 2021 05; 9(5). de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. PMID: 33980590; PMCID: PMC8118032.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    19. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clin Sci (Lond). 2021 03 12; 135(5):703-724. Baik AH, Tsai KK, Oh DY, Aras MA. PMID: 33686402; PMCID: PMC8647663.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    20. CD38 as a Novel Immunosuppressive Target in Prostate Cancer. Eur Urol. 2021 06; 79(6):747-749. Oh DY. PMID: 33637364.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):442-442. Koshkin KV, Natesan ND, Zhang ZL, Oh OD, Porten PS, Meng MM, Pruthi PR, Aggarwal AR, Small SE, Fong FL, Friedlander FT. .
      View in: Publisher Site   Mentions:
    22. TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):476-476. de Kouchkovsky dI, Zhang ZL, Philip PE, Wright WF, Kim KD, Natesan ND, Kwon KD, Ho HH, Ho HS, Chan CE, Porten PS, Desai DA, Huang HF, Chou CJ, Oh OD, Pruthi PR, Fong FL, Small SE, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    23. Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patients. Cancer Immunol Immunother. 2021 Jul; 70(7):2095-2102. Naidus E, Bouquet J, Oh DY, Looney TJ, Yang H, Fong L, Standifer NE, Zhang L. PMID: 33420629; PMCID: PMC8195930.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    24. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 12 01; 26(23):6204-6214. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. PMID: 32967941; PMCID: PMC7710628.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    25. Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T. Cancer Immunol Res. 2020 12; 8(12):1496-1507. Zhang L, Kandadi H, Yang H, Cham J, He T, Oh DY, Sheikh NA, Fong L. PMID: 32967912; PMCID: PMC7903967.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    26. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Mol Imaging Biol. 2020 12; 22(6):1553-1561. Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ. PMID: 32813112; PMCID: PMC7669684.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    27. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020 06 25; 181(7):1612-1625.e13. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. PMID: 32497499; PMCID: PMC7321885.
      View in: PubMed   Mentions: 260     Fields:    Translation:HumansCells
    28. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. J Immunother Cancer. 2020 05; 8(1). Cham J, Zhang L, Kwek S, Paciorek A, He T, Fong G, Oh DY, Fong L. PMID: 32376721; PMCID: PMC7223469.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    29. Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):502-502. Philip PE, Wright WF, Kim KD, Kwon KD, Ho HH, Ho HS, Cheung CE, Chan CE, Porten PS, Wong WA, Borno BH, Desai DA, Chou CJ, Oh OD, Aggarwal AR, Fong FL, Small SE, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    30. Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):187-187. Kwon KD, Wright WF, Zhang ZL, Chou CJ, Borno BH, Desai DA, Oh OD, Pollock PY, Bose BR, Huang HF, Hope HT, Friedlander FT, Fong FL, Feng FF, Small SE, Aggarwal AR, Koshkin KV. .
      View in: Publisher Site   Mentions:
    31. TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer. Front Immunol. 2019; 10:2985. Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, Fong L, Zhang L. PMID: 31993050; PMCID: PMC6962348.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    32. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin. Dig Dis Sci. 2019 03; 64(3):685-688. Hammami MB, Gill R, Thiruvengadam N, Oh DY, Beck K, Mahadevan U, Kattah MG. PMID: 30778872.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019 02 19; 50(2):477-492.e8. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. PMID: 30737146; PMCID: PMC6886475.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    34. Immunity in the Time of Metastases. Immunity. 2018 12 18; 49(6):1002-1003. Oh DY, Fong L. PMID: 30566878.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. Oncoimmunology. 2019; 8(1):e1486953. Hagihara K, Chan S, Zhang L, Oh DY, Wei XX, Simko J, Fong L. PMID: 30546940; PMCID: PMC6287789.
      View in: PubMed   Mentions: 13     Fields:    
    36. Abstract 4688: Single-cell discrimination of altered human T cell states in the bladder tumor microenvironment. Immunology. 2018 Jul 1; 4688-4688. Oh OD, Kwek KS, Mangul MS, Raju RS, Targ TS, Burra BA, Chow CE, Aran AD, Porten PS, Meng MM, Friedlander FT, Ye YC, Fong FL. .
      View in: Publisher Site   Mentions:
    37. Abstract 549: Clustering analysis of next-generation sequencing T cell repertoire data in sipuleucel-T treated prostate cancer patients. Bioinformatics and Systems Biology. 2017 Jul 1; 549-549. Zhang ZL, Chakraborty CS, Cham CJ, Oh OD, Sheikh SN, Fong FL. .
      View in: Publisher Site   Mentions:
    38. Abstract 1694: Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment increases T cell receptor diversity in localized and metastatic prostate cancer patients. Immunology. 2017 Jul 1; 1694-1694. Oh OD, Zhang ZL, Cham CJ, Paciorek PA, Klinger KM, Faham FM, Slovin SS, Fong FL. .
      View in: Publisher Site   Mentions:
    39. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. Cancer Res. 2017; 77(6):1322-1330. Oh DY, * Cham J, * Zhang L, Fong G, Kwek SS, Klinger M, Faham M, Fong L. *co-first author.
    40. Abstract 4362: T cell repertoire diversification is associated with immune related toxicities following immune checkpoint inhibition in metastatic cancer patients. Immunology. 2016 Jul 15; 4362-4362. Oh OD, Cham CJ, Zhang ZL, Fong FG, Klinger KM, Faham FM, Fong FL. .
      View in: Publisher Site   Mentions:
    41. Association between T cell repertoire diversification and both clinical response as well as toxicity following immune checkpoint blockade in metastatic cancer patients. Journal of Clinical Oncology. 2016 May 20; 34(15_suppl):3029-3029. Oh OD, Cham CJ, Zhang ZL, Fong FG, Klinger KM, Faham FM, Fong FL. .
      View in: Publisher Site   Mentions:
    42. On the Verge: Immunotherapy for Colorectal Carcinoma. J Natl Compr Canc Netw. 2015 Aug; 13(8):970-8. Oh DY, Venook AP, Fong L. PMID: 26285242.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    43. Differential contribution of chemotaxis and substrate restriction to segregation of immature and mature thymocytes. Immunity. 2009; 31(6):986-98. Ehrlich LI, * Oh DY, * Weissman IL, Lewis RS. *co-first author.
    44. Calcium oscillations regulate thymocyte motility during positive selection in the three-dimensional thymic environment. Nat Immunol. 2005 Feb; 6(2):143-51. Bhakta NR, Oh DY, Lewis RS. PMID: 15654342.
      View in: PubMed   Mentions: 109     Fields:    Translation:AnimalsCells
    45. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003 Mar 07; 112(5):659-72. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. PMID: 12628186.
      View in: PubMed   Mentions: 209     Fields:    Translation:HumansCells
    46. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem. 2001 Nov 16; 276(46):43285-93. Beresford PJ, Zhang D, Oh DY, Fan Z, Greer EL, Russo ML, Jaju M, Lieberman J. PMID: 11555662.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    47. A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J Immunol. 2000; 165(12):6915-21. Gommerman JL, * Oh DY, * Zhou X, Tedder TF, Maurer M, Galli SJ, Carroll MC. *co-first author.
    David's Networks
    Concepts (195)
    Derived automatically from this person's publications.
    _
    Co-Authors (75)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _